证券日报网讯 2月26日，珍宝岛在互动平台回答投资者提问时表示，公司截至2026年2月13日A股股东人 数为29081户。 （文章来源：证券日报） ...

证券日报网讯 2月24日，珍宝岛在互动平台回答投资者提问时表示，公司截至2026年2月10日A股股东人 数为29297户。 （文章来源：证券日报） ...

格隆汇2月24日丨珍宝岛(603567.SH)跌0.37%，报8.100元，股价创历史新低，总市值76.22亿元。 ...

五成公司预告盈利药明康德、三生国健等预盈超10亿 以业绩预告净利润下限统计，已公布2025年业绩预告的274家医药生物上市公司中，137家预计实现盈利，占比五成。 其中，10家公司预告归母净利润超10亿元，包括药明康德、三生国健、吉林敖东等。 新华财经北京2月24日电截至2026年2月12日，根据申万行业分类，A股医药生物行业逾500家上市公司，其中约274家已披露2025年业绩预告。 整体来看，已披露2025年业绩预告的274家医药生物上市公司中，业绩偏正面（包括预增、略增、扭亏及续盈）的企业合计90家。 137家医药生物上市公司2025年实现盈利，占比50%，其中10家归母净利润超10亿元。 图1：A股医药生物行业上市公司2025年业绩预告类型 图3：药明康德2025年度业绩预告 | | 2025年预告利润超过10亿元 | | | --- | --- | --- | | 证券代码 | 证券简称 | 业绩预告类型 | | 603259.SH | 药明康德 | 预增 | | 688336.CH | 三生国健 | 预增 | | 000623.SZ | 吉林敖东 | 预增 | | 688578.SH | 艾力斯 ...

以上内容基于公开资料整理，不构成投资建议。 受业绩利空影响，珍宝岛股价近7日连续下跌，区间跌幅达3.91%，2月12日收盘价8.12元，单日跌 1.81%。资金面呈净流出态势，2月12日主力资金净流出1138.8万元，散户资金占比36%。技术面显示股 价处于空头行情，均线系统呈空头排列，20日压力位9.33元，支撑位7.96元，表现弱于医药生物板块和 大盘。 近期事件 控股股东权益变动：2026年2月6日公告，控股股东创达集团因可交换债换股，持股比例从56.98%被动 降至55.86%，但控制权未发生变化。股份质押补充：2月10日公告，创达集团累计质押股份占比 80.48%，新增补充质押117万股以保障可交换债担保。行业政策发布：2月6日工信部等部委推出《中药 工业高质量发展方案(2026-2030)》，强调全产业链升级，与珍宝岛布局契合，但短期对业绩提振作用有 限。 经济观察网珍宝岛（603567）于2026年2月6日发布2025年业绩预告，预计归属净利润亏损10.12亿元至 11.73亿元，同比由盈转亏，创上市以来首次年度亏损。亏损主因中成药集采执标延后、医保控费导致 收入同比下降53%，毛利下降93%， ...

Core Viewpoint - The traditional Chinese medicine company Zhenbaodao Pharmaceutical is expected to report a net loss of between 1.012 billion and 1.173 billion yuan for the fiscal year 2025, marking its first annual loss since its listing in 2015, nearly erasing the total net profit from the previous three years [1][10] Financial Performance - The company's revenue peaked at 4.219 billion yuan in 2022 but plummeted by 25.5% to 3.144 billion yuan in 2023, with a further decline of 13.84% to 2.707 billion yuan in 2024, falling below 2018 levels. In the first three quarters of 2025, revenue dropped by 54.73% to only 919 million yuan, indicating a trend towards a historical low for the year [2][11] - The net profit, excluding non-recurring gains and losses, turned negative for the first time in 2022, with a loss of 280 million yuan. Although the loss narrowed to 31.84 million yuan in 2023, the downward trend continued, with an expected loss of between 1.073 billion and 1.234 billion yuan in 2025 [4][13] Asset Structure and Risks - The company faces significant asset structure risks, with accounts receivable reaching 3.111 billion yuan by the end of September 2025, while revenue for the same period was only 919 million yuan, resulting in a ratio of accounts receivable to revenue of 338.52%. This ratio has been on the rise in recent years [4][13] - Inventory levels surged from 1.005 billion yuan in Q3 2023 to 1.521 billion yuan in Q3 2025, reflecting a more than 50% year-on-year increase, indicating severe sales obstacles and inventory accumulation issues [4][13] Operational Efficiency - The company's operational efficiency has deteriorated, with inventory turnover days and accounts receivable turnover days reaching historical highs of 692.31 days and 919.37 days, respectively, more than doubling compared to the previous year [5][14] Impairment Losses - Zhenbaodao plans to recognize approximately 395 million yuan in credit impairment losses and about 266 million yuan in asset impairment losses, with these combined losses exceeding 660 million yuan, significantly impacting annual performance [7][16] Business Challenges - Core products have been included in the national centralized procurement of traditional Chinese medicine, coupled with increased pressure from national medical insurance cost control, leading to significant price reductions. The anticipated volume increase through price reductions has not materialized, resulting in a decline in both volume and price [7][16] Research and Development - Despite attempts to explore new growth avenues, the company has significantly reduced R&D investments, with R&D expenses dropping by 52.64% to 37.99 million yuan in 2024, accounting for only 2.60% of revenue, far below industry leaders [8][17] - The company announced plans to invest over 400 million yuan in building an R&D platform for innovative drugs, but actual investment progress has been slow, with only 92.17 million yuan spent by mid-2025, representing 26.26% of the planned investment [8][17] Dividend Policy and Governance Issues - Zhenbaodao has maintained a rigid cash dividend policy, distributing a total of 1.302 billion yuan since its listing, despite deteriorating fundamentals. In 2023 and 2024, the company distributed 188 million yuan and 141 million yuan, respectively [9][18] - The concentrated ownership structure raises concerns, as the largest beneficiary of dividends is the controlling shareholder, with a high pledge ratio of 81% for the controlling shareholder's equity, increasing financial risks [9][18] - Governance issues were highlighted by a lack of proper procedures in a significant 425 million yuan subsidiary equity transfer, exposing internal control deficiencies [10][19] Conclusion - Zhenbaodao Pharmaceutical is facing severe challenges due to industry changes, internal governance issues, and actions by major shareholders, necessitating a balance between short-term returns and long-term development to restore fundamentals and rebuild market trust [10][19]

Core Viewpoint - The announcement details a change in the equity structure of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. due to the passive reduction of shares held by its controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., following the conversion of exchangeable bonds [2][3]. Group 1: Equity Change Overview - After the equity change, Heilongjiang Chuangda Group holds 516,973,085 shares, representing 54.94% of the total share capital of Zhenbaodao [2][3]. - The equity change is a result of the conversion of exchangeable bonds issued by Chuangda Group, leading to a decrease in its shareholding from 55.86% to 54.94% [3][4]. Group 2: Details of the Equity Change - From February 5 to February 9, 2026, a total of 8,709,675 shares were converted, accounting for approximately 0.93% of the total share capital [4][11]. - The equity change does not trigger a mandatory tender offer and will not alter the controlling shareholder or actual controller of the company [2][5]. Group 3: Future Plans and Compliance - Chuangda Group's exchangeable bonds are currently in the conversion period, and the company will continue to monitor the conversion activities [5][8]. - The company has committed to fulfilling its information disclosure obligations in accordance with relevant laws and regulations [5][8].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603567 证券简称：珍宝岛 公告编号：临 2026-011 黑龙江珍宝岛药业股份有限公司 关于控股股东权益变动的提示性公告 本次权益变动后，黑龙江创达集团有限公司（以下简称"创达集团"）持有黑 龙江珍宝岛药业股份有限公司（以下简称"公司"或"珍宝岛"）股份 516,973,085 股，占公司总股本的 54.94%。 本次权益变动属于创达集团发行的可交换公司债券持有人换股造成权益变动 人被动减持，不触及要约收购，不会导致公司控股股东及实际控制人发生变化。 一、本次权益变动基本情况 公司于近日收到控股股东创达集团的《简式权益变动报告书》，获悉创达集团发 行的 2023 年面向专业投资者非公开发行可交换公司债券（第一期）（以下简称"第 一期可交换债券"）和 2023 年面向专业投资者非公开发行可交换公司债券（第二期） （以下简称"第二期可交换债券"）的债券持有人发生换股，导致创达集团持股比例 被动下降，持有公司股份比例从 55.86%减少至 54.94%， ...

简式权益变动报告书 黑龙江珍宝岛药业股份有限公司 上市公司名称:黑龙江珍宝岛药业股份有限公司 股票上市地点:上海证券交易所 股票简称：珍宝岛 股票代码：603567 信息披露义务人：黑龙江创达集团有限公司 住所/通讯地址：虎林市解放西街北检察院东侧宝润香林里1号楼1号门市 股份变动性质：股份减少 签署日期：2026年2月9日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》《上市公司收 购管理办法》《公开发行证券的公司信息披露内容与格式准则第15号——权益变动 报告书》等相关法律、法规和规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行证 券的公司信息披露内容与格式准则第15号——权益变动报告书》的规定，本报告书 已全面披露信息披露义务人在黑龙江珍宝岛药业股份有限公司中拥有权益的股份变 动情况。 | 公司、上市公司、珍宝岛 | 指 | 黑龙江珍宝岛药业股份有限公司 | | --- | --- | --- | | 信息披露义务人、创达集团 | 指 | 黑龙江创达集团有限公司 | | "23创01 ...

Core Viewpoint - The announcement indicates a reduction in shareholding by Heilongjiang Chuangda Group Co., Ltd. due to the exchange of corporate bonds, resulting in a decrease in ownership percentage from 55.86% to 54.94% [1] Group 1 - Heilongjiang Chuangda Group Co., Ltd. has reduced its shareholding by 8.7097 million shares during the period from February 5 to February 9, 2026 [1] - After the equity change, Chuangda Group holds a total of 516,973,085 shares, representing 54.94% of the company's total equity [1]